Merck Serono: Erbitux Indication Extension Submitted for 1st-Line Advanced or Metastatic NSCLC in the EU

DARMSTADT, Germany--(BUSINESS WIRE)--Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that it has submitted an indication extension to the European Medicines Agency (EMA) for the approval of Erbitux® (cetuximab) in combination with standard 1st line platinum-based chemotherapy in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with high epidermal growth factor receptor (EGFR) expression.